Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Yin, Guowen

DOI: https://doi.org/10.1007/s12325-023-02449-6

2023-02-21

Advances in Therapy

Abstract:This study evaluated the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib plus programmed death (PD)-1 inhibitor (TACE-L-P) versus TACE combined with sorafenib plus PD-1 inhibitor (TACE-S-P) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).

pharmacology & pharmacy,medicine, research & experimental

What problem does this paper attempt to address?

This paper aims to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib plus programmed death - 1 (PD - 1) inhibitor (TACE - L - P) and TACE combined with sorafenib plus PD - 1 inhibitor (TACE - S - P) in the treatment of patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT).

Specifically, the main objectives of the study include:
1. **Comparing the effectiveness of the two treatment regimens**: Measured by evaluating the objective response rate (ORR), disease control rate (DCR), progression - free survival (PFS) and overall survival (OS) of patients.
2. **Evaluating safety**: Recording and analyzing treatment - related adverse events (AEs), especially the incidence and severity of grade 3 - 4 toxic reactions.
3. **Exploring the influence of inflammatory mediators on treatment efficacy**: By detecting changes in blood biochemical indicators before and after treatment, analyzing whether inflammatory factors such as interleukin - 17 (IL - 17), vascular endothelial growth factor (VEGF), procalcitonin (PCT) and C - reactive protein (CRP) affect treatment efficacy.

The research results show that the TACE - L - P group is superior to the TACE - S - P group in many aspects, including a longer median OS (21.7 months vs. 15.6 months, P = 0.0027), a longer median PFS (6.3 months vs. 3.2 months, P < 0.0001), a higher ORR (41.25% vs. 30.59%, P = 0.008) and a higher DCR (86.25% vs. 62.35%, P = 0.008). Multivariate analysis further indicates that PVTT classification, Child - Pugh grade, IL - 17, VEGF, PCT and CRP are independent prognostic factors affecting patient OS.

In conclusion, this study has proven that TACE - L - P has better efficacy and acceptable safety in the treatment of HCC patients with PVTT, but higher inflammatory indicators will affect the treatment effect. These findings provide an important reference basis for clinically selecting more effective treatment regimens.